Biologica Technologies to showcase latest data for ProteiOS® growth factor

Monday, April 30, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

CARLSBAD, Calif., April 30, 2018 /PRNewswire/ -- Biologica Technologies, LLC (the "Company" or "Biologica") announced today

that they will be exhibiting their first pieces of clinical data for ProteiOS growth factor at this week's American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in New Orleans, LA.  Biologica
will be located in Booth #846.

ProteiOS is a unique, first of its kind allograft-derived growth factor that offers a number of distinct advantages over current products in the osteobiologic market.  It provides an array of osteoinductive, angiogenic and mitogenic growth factors in a lyophilized powder form that when rehydrated allows a surgeon great flexibility of using their osteoconductive scaffold of choice.  ProteiOS was recently launched via a targeted release in Q4 of 2017 and is now available nationwide across the USA. 

"We are pleased to highlight our latest product and its early clinical data in spine," said Amit Govil, President of Biologica.  "We look forward to meeting surgeons and sales distributors that are keen to understand how ProteiOS can fit into their practices and accounts and how it provides a number of unique benefits as compared to other biological options available today." 

About Biologica Technologies Biologica Technologies is a company focused on providing clinically relevant biologic solutions across the orthopaedic and aesthetic specialty markets.  Biologica has developed innovative and ground breaking methods to access the naturally occurring growth factors found within allograft tissue, with ProteiOS growth factor being their first introduction into the orthopaedic and neurosurgery markets.

 

Cision View original content:http://www.prnewswire.com/news-releases/biologica-technologies-to-showcase-latest-data-for-proteios-growth-factor-300638729.html

SOURCE Biologica Technologies, LLC

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store